118 related articles for article (PubMed ID: 19748230)
1. Candida albicans isolates from APECED patients show decreased susceptibility to miconazole.
Siikala E; Richardson M; Pfaller MA; Diekema DJ; Messer SA; Perheentupa J; Saxén H; Rautemaa R
Int J Antimicrob Agents; 2009 Dec; 34(6):607-9. PubMed ID: 19748230
[No Abstract] [Full Text] [Related]
2. Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients.
Rautemaa R; Richardson M; Pfaller M; Koukila-Kähkölä P; Perheentupa J; Saxén H
J Antimicrob Chemother; 2007 Oct; 60(4):889-92. PubMed ID: 17704513
[TBL] [Abstract][Full Text] [Related]
3. Action of miconazole at high concentrations against Candida albicans.
D'Auria FD; Villa A; Simonetti N
J Chemother; 1989 Jul; 1(4 Suppl):240-2. PubMed ID: 16312385
[No Abstract] [Full Text] [Related]
4. Persistent Candida albicans colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients.
Siikala E; Rautemaa R; Richardson M; Saxen H; Bowyer P; Sanglard D
J Antimicrob Chemother; 2010 Dec; 65(12):2505-13. PubMed ID: 20876623
[TBL] [Abstract][Full Text] [Related]
5. Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole.
Rautemaa R; Richardson M; Pfaller M; Perheentupa J; Saxen H
Scand J Infect Dis; 2008; 40(11-12):904-7. PubMed ID: 18651265
[TBL] [Abstract][Full Text] [Related]
6. [The comparison of susceptibility of Candida albicans and Candida glabrata to miconazole].
Kurnatowski P; Makieło L; Horwatt-Bozyczko E
Wiad Parazytol; 2001; 47(4):867-73. PubMed ID: 16886440
[TBL] [Abstract][Full Text] [Related]
7. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility and trailing growth of Candida albicans to fluconazole: results of a Korean multicentre study.
Lee MK; Kim HR; Kang JO; Kim MN; Kim EC; Kim JS; Kim JJ; Park YJ; Song W; Shin JH; Lee KM; Lee NY; Lee M; Lee WG; Lee CK; Lee HJ; Chang CL; Choi TY
Mycoses; 2007 Mar; 50(2):148-9. PubMed ID: 17305780
[TBL] [Abstract][Full Text] [Related]
9. [Assessment of the sensitivity to antifungal agents of clinical isolates of Candida albicans serotype A and B by the ATB Fungus method].
Quindós G; San Millán R; Burgos A; Lipperheide V; Tellaetxe M; Alonso R; Barturen B; Pontón J
Enferm Infecc Microbiol Clin; 1995 Apr; 13(4):209-12. PubMed ID: 7779872
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility to 5-fluorocytosine, miconazole and amphotericin B of Candida albicans strains isolated from the throat of non-AIDS patients.
Paniagua GL; Monroy E; Negrete E; Vaca S
Rev Latinoam Microbiol; 2002; 44(2):65-8. PubMed ID: 17063773
[TBL] [Abstract][Full Text] [Related]
11. Isolation, characterization and antifungal susceptibility pattern of Candida species causing oropharyngeal candidiasis in HIV positive patients.
Maninder J; Usha A
J Commun Dis; 2008 Sep; 40(3):177-81. PubMed ID: 19245155
[TBL] [Abstract][Full Text] [Related]
12. [Investigation of quantitative and species composition and antifungal drug susceptibility of yeasts isolated from patients with generalized periodontitis complicated by candidosis].
Kutsyk RV; Pavliuk TD
Mikrobiol Z; 2003; 65(5):26-9. PubMed ID: 14723159
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of Candida albicans biofilms grown in a constant depth film fermentor to chlorhexidine, fluconazole and miconazole: a longitudinal study.
Lamfon H; Porter SR; McCullough M; Pratten J
J Antimicrob Chemother; 2004 Feb; 53(2):383-5. PubMed ID: 14729749
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of using collagen as the base of the antifungal drug, miconazole.
Yoshida K; Hirai K; Ara T; Ito M; Wang PL; Igarashi Y
J Oral Rehabil; 2006 May; 33(5):363-7. PubMed ID: 16629895
[TBL] [Abstract][Full Text] [Related]
16. Azole resistance in Candida albicans.
Smith KJ; Warnock DW; Kennedy CT; Johnson EM; Hopwood V; Van Cutsem J; Vanden Bossche H
J Med Vet Mycol; 1986 Apr; 24(2):133-44. PubMed ID: 3014106
[TBL] [Abstract][Full Text] [Related]
17. [The relationship between Candida albicans 25S intron genotypes and antifungal susceptibilities].
Balaban N; Karahan ZC; Mumcuoğlu I; Cayirli A; Kuştimur S
Mikrobiyol Bul; 2007 Apr; 41(2):245-51. PubMed ID: 17682711
[TBL] [Abstract][Full Text] [Related]
18. [Study on classification and treatment of vulvovaginal candidiasis].
Fan SR; Liu XP; Li JW; Xu AP; Liu M
Zhonghua Fu Chan Ke Za Zhi; 2005 Aug; 40(8):532-5. PubMed ID: 16202291
[TBL] [Abstract][Full Text] [Related]
19. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy.
Shahid Z; Sobel JD
Diagn Microbiol Infect Dis; 2009 Jul; 64(3):354-6. PubMed ID: 19501794
[TBL] [Abstract][Full Text] [Related]
20. The effects of miconazole on the ultrastructure of Candida albicans.
De Nollin S; Borgers M; Van Belle H
Proc R Soc Med; 1977; 70 Suppl 4(Suppl 4):19-23. PubMed ID: 122689
[No Abstract] [Full Text] [Related]
[Next] [New Search]
